ImmunityBio (IBRX) Total Non-Current Liabilities (2013 - 2026)

ImmunityBio (IBRX) has 14 years of Total Non-Current Liabilities data on file, last reported at $1.5 billion in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $1.5 billion, up 68.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 68.6% YoY), and the FY2025 annual result was $1.0 billion, up 16.07% from the prior year.
• Total Non-Current Liabilities grew to $1.5 billion in Q1 2026 per IBRX's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $1.5 billion in Q1 2026 and troughed at $726.9 million in Q1 2022.
• A 5-year average of $942.7 million and a median of $908.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 93.69% in 2022, then declined 18.82% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $790.5 million in 2022, then grew by 22.91% to $971.6 million in 2023, then fell by 11.23% to $862.5 million in 2024, then rose by 16.07% to $1.0 billion in 2025, then soared by 49.09% to $1.5 billion in 2026.
• Business Quant data shows IBRX's Total Non-Current Liabilities at $1.5 billion in Q1 2026, $1.0 billion in Q4 2025, and $927.2 million in Q3 2025.